Evidence map›Paper›PMID 26098902›Full record

ArticlePloS one2015

Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy.

Josué Rakotonjanahary, Emilie De Carli, Matthieu Delion, Chantal Kalifa, Jacques Grill, François Doz, Pierre Leblond, Anne-Isabelle Bertozzi, Xavier Rialland, Brain Tumor Committee of SFCE

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Surgical Treatment of Optic Pathway Hypothalamic Gliomas.Advances and technical standards in neurosurgery · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Comparison of the clinical features and treatment outcomes of pilocytic astrocytoma in pediatric and adult patients.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Novel treatments in optic pathway gliomas.Frontiers in ophthalmology · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Josué RakotonjanaharyDepartment of Pediatric Oncology, University Hospital, Angers, France; INSERM CIE5 Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Diderot, Sorbonne Paris Cité, Paris, France.
Emilie De CarliDepartment of Pediatric Oncology, University Hospital, Angers, France.
Matthieu DelionDepartment of Neurosurgery, University Hospital, Angers, France.
Chantal KalifaDepartment of Pediatric and Adolescent Oncology, Gustave Roussy Institute, Villejuif, France.
Jacques GrillDepartment of Pediatric and Adolescent Oncology, Gustave Roussy Institute, Villejuif, France.
François DozDepartment of Pediatric Oncology, Curie Institute and University Paris Descartes, Sorbonne Paris Cité, Paris, France.
Pierre LeblondDepartment of Pediatric Oncology, Oscar Lambret Center, Lille, France.
Anne-Isabelle BertozziDepartment of Pediatric Oncology, University Hospital, Toulouse, France.
Xavier RiallandDepartment of Pediatric Oncology, University Hospital, Angers, France.
Brain Tumor Committee of SFCE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn terms of overall survival (OS), limited data are available for the very long-term outcomes of children treated for optic pathway glioma (OPG) with up-front chemotherapy. Therefore, we undertook this study with the aim of clarifying long-term OS and causes of death in these patients.

methodsWe initiated and analyzed a historical cohort study of 180 children with OPG treated in France with BB-SFOP chemotherapy between 1990 and 2004. The survival distributions were estimated using Kaplan-Meier method. The effect of potential risk factors on the risk of death was described using Cox regression analysis.

resultsThe OS was 95% [95% CI: 90.6-97.3] 5 years after diagnosis and significantly decreased over time without ever stabilizing: 91.6% at 10 years [95% CI: 86.5-94.8], 80.7% at 15 years [95% CI: 72.7-86.8] and 75.5% [95% CI: 65.6-83] at 18 years. Tumor progression was the most common cause of death (65%). Age and intracranial hypertension at diagnosis were significantly associated with a worse prognosis. Risk of death was increased by 3.1[95% CI: 1.5-6.2] (p=0.002) for patients less than 1 year old at diagnosis and by 5.2[95% CI: 1.5-17.6] (p=0.007) for patients with initial intracranial hypertension. Boys without diencephalic syndrome had a better prognosis (HR: 0.3 [95% CI: 0.1-0.8], p=0.007).

conclusionsThis study shows that i) in children with OPG, OS is not as favorable as previously described and ii) patients can be classified into 2 groups depending on risk factors (age, intracranial hypertension, sex and diencephalic syndrome) with an OS rate of 50.4% at 18 years [95% CI: 31.4-66.6] in children with the worst prognosis. These findings could justify, depending on the initial risk, a different therapeutic approach to this tumor with more aggressive treatment (especially chemotherapy) in patients with high risk factors.

Indexed as

Drug Therapy, CombinationAntineoplastic AgentsAstrocytomaCarboplatinChildChild, PreschoolCisplatinCohort StudiesCyclophosphamideDisease-Free SurvivalEtoposideFemaleFranceHumansInfantMaleAntineoplastic AgentsCarboplatinCisplatinCyclophosphamideEtoposideProcarbazineVincristine

Identifiers

PMID26098902
PMCPMC4476571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.